MDIT - Medite Cancer Diagnostics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2017
12/30/2016
12/30/2015
Total Revenue
8,133
6,813
9,238
9,887
Cost of Revenue
6,205
6,651
5,608
6,084
Gross Profit
1,928
162
3,630
3,803
Operating Expenses
Research Development
716
1,188
1,477
1,278
Selling General and Administrative
4,944
5,161
3,600
2,947
Total Operating Expenses
5,941
6,642
5,291
4,402
Operating Income or Loss
-4,013
-6,480
-1,661
-599
Interest Expense
-
-
-
-
Total Other Income/Expenses Net
233
31
60
-22
Income Before Tax
-5,813
-7,298
-2,295
-781
Income Tax Expense
-487
-487
-132
78
Income from Continuing Operations
-5,326
-6,811
-2,163
-859
Net Income
-5,326
-6,811
-2,163
-859
Net Income available to common shareholders
-5,417
-6,902
-2,254
-937
Reported EPS
Basic
-
-0.26
-0.11
-0.05
Diluted
-
-0.26
-0.11
-0.05
Weighted average shares outstanding
Basic
-
26,436
21,424
20,195
Diluted
-
26,436
21,424
20,195
EBITDA
-
-6,187
-1,447
-422